CSL Stock Price Prediction 2025, 2026, 2030, 2040, 2050
CSL is a global biotechnology company situated in Melbourne, Australia. It makes products that help treat and prevent serious health problems. The company has different parts for different treatment products. CSL Behring, which makes treatment products for rare diseases like haemophilia and immune problems; CSL Seqirus, which is one of the largest makers of flu vaccines; CSL Vifor, which provides treatments for iron deficiency and kidney disease; and CSL Plasma, which collects plasma used to make medicines. Its products, including blood treatments, vaccines, and antivenoms, are available in over 100 countries.
What is CSL Ltd ASX: CSL?
CSL was established in 1916, situated in Melbourne, Australia. It is a global company that makes important medicines for serious health problems. It has four main areas: CSL Behring, which helps treat rare diseases, CSL Plasma, which collects blood plasma to make medicines, CSL Seqirus, which makes flu vaccines, and CSL Vifor, which helps with iron and kidney treatments. It operates in over 100 countries. The company invests a lot in research to develop new treatments and uses technology like artificial intelligence to make better medicines. It is also building a new flu vaccine factory near Melbourne and helping new biotech companies.
CSL Stock Price Prediction Tomorrow
From the previous year, the stock has fallen much. It continuously made lower low swings. Till now, not a single swing has been broken. The stock tried while showing some bullish moves, but after a few days, it could not sustain there and fell. To buy this stock, you should wait for its trend reversal.
| Day | Minimum Price (AUD) | Maximum Price (AUD) |
| Tomorrow | -$3.71 | +$6.89 |
Aristocrat Leisure Stock Price Prediction 2025
It makes and sells special medicines and vaccines. It helps treat health problems like bleeding disorders, weak immune systems, low iron levels, kidney disease, and the flu. It uses advanced tools like blood plasma, proteins, gene and cell treatments to create its products. The company focuses on treating the blood, lungs, heart, kidneys, and immune system. It works in many countries, including Australia, the US, China, and the UK. In 2025, its stock price would be $297, as per our analysis.
By our prediction, its stock price would be between $208 to $297 in 2025.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2025 | $208 | $297 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $268 | $290 |
| February | $253 | $277 |
| March | $246 | $265 |
| April | $228 | $262 |
| May | $220 | $268 |
| June | $215 | $270 |
| July | $208 | $273 |
| August | $225 | $278 |
| September | $246 | $283 |
| October | $257 | $286 |
| November | $268 | $290 |
| December | $279 | $297 |
Stock Price Prediction 2026
It is one of the biggest biotech companies in the world. It uses proteins that come from blood plasma. These treatments help people with health problems like weak immune systems, bleeding issues, and some nerve-related conditions. It also makes flu vaccines and is now the second biggest flu vaccine company in the world. It is very good at research and creating new medicines. The company has a lot of different products now, and it’s also working on new ones that don’t use plasma. In 2026, its stock price would be $394, as per our prediction.
Its stock price would be between $279 and $394 in 2026, as per our analysis.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2026 | $279 | $394 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $279 | $307 |
| February | $287 | $313 |
| March | $289 | $320 |
| April | $298 | $324 |
| May | $310 | $333 |
| June | $318 | $340 |
| July | $322 | $346 |
| August | $330 | $355 |
| September | $334 | $367 |
| October | $338 | $373 |
| November | $349 | $380 |
| December | $362 | $394 |
Stock Price Prediction 2027
It is developing new medicines such as Garadacimab, Hizentra, and Anumigilumab for immune system diseases. It also does business with medicines made by other companies, like Eblasakimab for skin problems, Mavrilimumab for joint and blood vessel diseases, and LASN01 for lung and eye problems. These partnerships help CSL do more than just its research. With teams working in science centres around the world, it also partners with universities, research groups, and other companies. It supports new ideas in medicine by working with start-ups and investors. In 2027, its stock price would be $492, as per our analysis.
By our prediction, its stock price would be between $362 to $492 in 2027.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2027 | $362 | $492 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $362 | $400 |
| February | $377 | $411 |
| March | $389 | $418 |
| April | $393 | $422 |
| May | $397 | $430 |
| June | $411 | $438 |
| July | $424 | $449 |
| August | $427 | $455 |
| September | $430 | $467 |
| October | $441 | $476 |
| November | $462 | $480 |
| December | $478 | $492 |
Stock Price Prediction 2028
It is focusing more on developing new medical treatments by investing in the Brandon BioCatalyst Fund 6. The company also opened a new head office and research centre in Melbourne, where more than 850 people work on creating new medicines. Around the world, it growing its partnerships by working with other comapny and open research offices. It ran many clinical trials in different medical areas and spent more money on research, showing its strong dedication to improving health. In 2028, its stock price would be $595, as per our prediction.
Its stock price would be between $478 and $595 in 2028, as per our analysis.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2028 | $478 | $595 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $478 | $498 |
| February | $487 | $509 |
| March | $497 | $514 |
| April | $500 | $522 |
| May | $503 | $529 |
| June | $511 | $540 |
| July | $518 | $549 |
| August | $527 | $563 |
| September | $530 | $577 |
| October | $541 | $580 |
| November | $551 | $584 |
| December | $566 | $595 |
Stock Price Prediction 2029
The company is dedicated to helping people with rare and serious diseases by making and providing safe, high-quality medicines. The company uses a Quality Management System (QMS) to make sure its products follow safety and quality rules around the world. This system includes rules and steps for how work is done across the company, including working with partners and suppliers, making and delivering products, and checking product safety even after they are sold. In 2029, its stock price would be $703, as per our analysis.
By our prediction, its stock price would be between $566 to $703 in 2029.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2029 | $566 | $703 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $566 | $608 |
| February | $578 | $615 |
| March | $588 | $624 |
| April | $597 | $630 |
| May | $611 | $637 |
| June | $617 | $644 |
| July | $625 | $651 |
| August | $637 | $660 |
| September | $648 | $670 |
| October | $644 | $681 |
| November | $668 | $688 |
| December | $681 | $703 |
CSL Stock Price Prediction 2030
When COVID-19 spread, it teamed up with AstraZeneca and the Australian government to make millions of doses of the COVID-19 vaccine in Australia. At the same time, its vaccine company, Seqirus, made more flu vaccines to help people stay safe from both the flu and COVID-19. It also works with the World Health Organisation and helps the world. The company helps create new vaccines using the latest science and technology. In 2030, its stock price would be $807, as per our prediction.
Its stock price would be between $681 and $807 in 2030, as per our analysis.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2030 | $681 | $807 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $681 | $710 |
| February | $689 | $717 |
| March | $697 | $724 |
| April | $707 | $730 |
| May | $711 | $738 |
| June | $719 | $743 |
| July | $725 | $750 |
| August | $733 | $761 |
| September | $740 | $778 |
| October | $758 | $783 |
| November | $770 | $790 |
| December | $778 | $807 |
CSL Stock Price Prediction 2040
The company is working harder. The company wants to reduce air pollution, cut down on waste, and use less energy in its buildings and factories. The company helps local communities, supports science education, spreads awareness about rare diseases, and makes healthcare easier to access for people in need. Each year, it shares a report to show how it is helping the environment and supporting people, using well-known international guidelines. In 2040, its stock price would be $1500, as per our analysis.
By our prediction, its stock price would be between $1364 to $1500 in 2040.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2040 | $1364 | $1500 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $1364 | $1388 |
| February | $1368 | $1398 |
| March | $1377 | $1411 |
| April | $1387 | $1427 |
| May | $1398 | $1438 |
| June | $1407 | $1442 |
| July | $1418 | $1450 |
| August | $1428 | $1464 |
| September | $1440 | $1470 |
| October | $1449 | $1479 |
| November | $1461 | $1488 |
| December | $1478 | $1500 |
CSL Stock Price Prediction 2050
CSL Seqirus was created in 2015 after it bought the flu vaccine part of another company. Since then, it has become one of the top flu vaccine makers in the world. Seqirus helps protect people from flu during regular seasons and pandemics by using advanced methods to make vaccines faster and more effective. The company is based in the UK and has large factories in the U.S., Europe, and Australia. Seqirus played an important role during health emergencies like COVID-19 by helping make and develop vaccines. In 2050, its stock price would be $2309, as per our prediction.
Its stock price would be between $2136 and $2309 in 2050, as per our analysis.
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2050 | $2136 | $2309 |
| Month | Minimum Price (AUD) | Maximum Price (AUD) |
| January | $2136 | $2168 |
| February | $2147 | $2177 |
| March | $2150 | $2189 |
| April | $2157 | $2198 |
| May | $2166 | $2208 |
| June | $2178 | $2219 |
| July | $2188 | $2238 |
| August | $2198 | $2255 |
| September | $2218 | $2274 |
| October | $2234 | $2281 |
| November | $2245 | $2288 |
| December | $2271 | $2309 |
Price Summary
| Year | Minimum Price (AUD) | Maximum Price (AUD) |
| 2025 | $208 | $297 |
| 2026 | $279 | $394 |
| 2027 | $362 | $492 |
| 2028 | $478 | $595 |
| 2029 | $566 | $703 |
| 2030 | $681 | $807 |
| 2040 | $1364 | $1500 |
| 2050 | $2136 | $2309 |
CSL earnings results
| (USD) | Dec 2024 | Sept 2024 | Jun 2024 | Mar 2024 |
| Revenue | 424.15Cr | 424.15Cr | 337.35Cr | 337.35Cr |
| Net income | 100.35Cr | 100.35Cr | 37.05Cr | 37.05Cr |
| Diluted EPS | 2.06 | 2.06 | 0.77 | 0.77 |
| Net profit margin | 23.66% | 23.66% | 10.98% | 10.98% |
| Operating income | 138.6Cr | 138.6Cr | 64.15Cr | 64.15Cr |
| Net change in cash | -5.95Cr | -5.95Cr | 31.6Cr | 31.6Cr |
| Cash on hand | – | – | – | – |
| Cost of revenue | 195.15Cr | 195.15Cr | 168.65Cr | 168.65Cr |
Expert forecasts on the future of CSL
The company is spending money on research, opening more places to collect plasma, and buying other companies like Vifor Pharma to grow. As more people need healthcare, it is in a good position to help. It is also working on new medicines for the immune system, blood problems, and lung diseases. There may be some problems, like rules and higher costs, but overall, it is a strong brand and ready for the future.
Is CSL stock good to buy? (bull case & bear case)
Bull Case:
- It expects strong profit growth this year (10–13% higher).
- The company makes money from blood products, vaccines, and iron treatments.
- It’s spending on new factories to grow in the future.
- Most experts think it’s a good stock and expect the price to go up.
- It is a global brand with steady, reliable business.
Bear Case:
- The stock price is already high compared to similar companies.
- It costs a lot to collect plasma, and that could impact its profits.
Conclusion
It is a large and trusted company that makes important medicines for people with serious health problems. It keeps doing research, building new factories, and working with other companies. It also uses new technology to make better treatments and help more people. Even though it has some challenges like high costs and rules to follow, the company is strong and stable.
